{"filings":[{"id":889156,"accession_number":"0001213900-26-065845","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-06-05T20:30:15+00:00","items":["5.07"],"status":"ready","headline":"Nektar Therapeutics holds 2026 annual meeting; all four proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Howard W. Robin elected director with 13,164,879 for, 4,975,288 against, 286,175 abstain; broker non-votes 4,588,835.","Equity plan amendment to increase authorized shares by 3,000,000 approved: 13,160,661 for, 4,902,925 against, 362,756 abstain.","Ratification of Ernst & Young as auditor for FY 2026 approved: 22,591,556 for, 118,592 against, 305,029 abstain.","Advisory say-on-pay resolution approved: 18,154,226 for, 161,005 against, 111,111 abstain; broker non-votes 4,588,835."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99629,"accession_number":"0001193125-26-214976","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M of common stock in at-the-market offerings.","Sandra Gardiner retiring as interim CFO effective May 15, 2026; Linda Rubinstein of FLG Partners will succeed her.","Rubinstein has over 35 years experience, raised >$5B in financings, and previously CFO of Adverum Biotechnologies.","Shares may be sold through ordinary brokers' transactions on Nasdaq at market prices; 3.0% commission fee to agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99628,"accession_number":"0001213900-26-053369","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q1 net loss $44.9M; cash $731.6M; rezpegaldesleukin Phase 3 to start July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.9M ($1.82 loss per share) vs $50.9M in Q1 2025.","Cash & investments $731.6M; excludes $351M net proceeds from April offering.","R&D $35.7M, G&A $13.4M; total operating costs $49.9M.","Phase 3 ZENITH-AD program in atopic dermatitis to initiate by July 2026.","Closed public offerings raising $460M in Feb and $373.8M in April."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":10861000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99627,"accession_number":"0001193125-26-171731","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nektar prices $325M upsized equity offering at $92/share; net proceeds ~$350.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Firm shares: 3,532,609 at $92.00; underwriters exercised option for 529,891 additional shares in full.","Net proceeds estimated at ~$350.9M after underwriting discounts and offering expenses.","Proceeds to fund general corporate purposes, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata.","Joint bookrunners include Jefferies, TD Cowen, Piper Sandler; Citigroup also bookrunner.","Offering expected to close on April 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99626,"accession_number":"0001193125-26-164186","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Nektar reports estimated cash and investments of $741.7M as of April 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities estimated at $741.7 million as of April 1, 2026.","Announcement is a preliminary estimate, not a comprehensive financial statement.","Amount based solely on information available as of April 20, 2026 filing date.","No other financial results or guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99625,"accession_number":"0001193125-26-162763","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar: REZOLVE-AA 52-wk SALT≤20 at 25.8% (low) and 27.6% (high) vs 6.7% placebo; p=0.049","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SALT≤20 responders nearly doubled from week 36: low dose 25.8% (from 14.8%), high dose 27.6% (from 15.6%), placebo unchanged at 6.7%.","SALT≤30 at wk52: 30.2% low, 35.0% high vs 8.4% placebo (p=0.023). SALT50: 37.7% low, 38.8% high vs 13.6% placebo.","94% of 31 patients completed 16-week extension; no discontinuations due to TEAEs. Injection site reactions mild-to-moderate, self-resolving within 5 days.","Nektar will submit results to a medical conference in 2026 and plans to advance rezpegaldesleukin into registrational trials in alopecia areata."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115747,"accession_number":"0001213900-26-027026","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar reports Q4 2025 net loss $36.1M ($1.78/sh); cash $245.8M plus $460M Feb 2026 offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue Q4 2025 $21.8M vs $29.2M YoY; full year $55.2M vs $98.4M.","Net loss Q4 2025 $36.1M ($1.78/sh) vs net income $7.3M ($0.52/sh) in Q4 2024; full year net loss $164.1M.","Cash and investments $245.8M at Dec 31, 2025; subsequent $460M secondary offering and $44M ATM in Feb/Mar 2026.","Phase 2b data for rezpegaldesleukin in atopic dermatitis and alopecia areata reported; Phase 3 to start Q2 2026.","Research collaboration with UCSF for NKTR-0165 in multiple sclerosis announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115746,"accession_number":"0001193125-26-049378","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nektar Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,603,449 common shares at $58.00 and 293,103 pre-funded warrants at $57.9999; gross proceeds $400M.","Underwriters exercised full option for 1,034,482 additional shares; net proceeds ~$432M after discounts/expenses.","Proceeds for general corporate purposes including Phase 3 trial for rezpegaldesleukin and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115745,"accession_number":"0001193125-26-044751","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Nektar Therapeutics reports $229.1M cash and investments as of Jan 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities totaled approximately $229.1 million as of January 31, 2026.","Announcement made on February 10, 2026 via a Regulation FD disclosure.","The amounts are estimates based on information available as of the announcement date.","Nektar Therapeutics (ticker: NKTR) listed on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115744,"accession_number":"0001193125-26-043755","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar REZOLVE-AD maintenance data show durable EASI-75/90, vIGA-AD responses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["71% (monthly) and 83% (quarterly) maintained EASI-75 on 24 µg/kg; 85% and 63% maintained vIGA-AD 0/1.","EASI-100 increased 2-5 fold: from 4% to 22% (monthly) and 9% to 18% (quarterly) in re-randomized patients.","Discontinuation rate due to AEs was 3.5%; injection site reactions mostly mild; no new safety concerns.","FDA alignment on Phase 3 design: 24 µg/kg Q2W induction, co-primary endpoints; start Q2 2026.","New responses at Week 52: 51% new EASI-75 (monthly) and 39% (quarterly) support prolonged therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115743,"accession_number":"0001213900-26-008210","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nektar enters quiet period ahead of Phase 2b REZOLVE-AD maintenance data; data expected in February 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quiet period begins January 27, 2026 and continues until public announcement of the maintenance data.","Maintenance Data are from the 36-week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin.","Next investor communication planned for February 2026 at the time of data presentation.","This quiet period is consistent with prior quiet periods for REZOLVE studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132169,"accession_number":"0001193125-25-320009","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar Phase2b REZOLVE-AA: primary endpoint missed; significant after excluding 4 violators. Plans Phase3.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean % SALT reduction at Week 36: 28.2% (24 µg/kg), 30.3% (18 µg/kg) vs 11.2% placebo (p=0.186, p=0.121).","Excluding 4 patients with major eligibility violations: 29.6%, 30.4% vs 5.7% (p=0.049, p=0.042), meeting significance.","Key secondary endpoints (SALT30, SALT≤30, SALT≤20, SALT≤10) showed dose-dependent improvement vs placebo.","Safety well-tolerated; discontinuation rate due to AEs 1.4%, no discontinuations from injection site reactions.","Plans to present results at a medical conference in 2026; 16-week extension data expected early Q2 2026; advancing to Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132168,"accession_number":"0001213900-25-113606","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nektar Therapeutics Chief Legal Officer Mark A. Wilson to Depart; Elizabeth Zhang to Succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark A. Wilson will step down as Chief Legal Officer, effective December 31, 2025.","Elizabeth Zhang, Vice President of Legal and Corporate Counsel, will take over Wilson's responsibilities.","Zhang joined Nektar in 2021 and previously worked at Cravath, Swaine & Moore and Gibson, Dunn & Crutcher.","Zhang holds a BA from Harvard College, an MS from the University of Oxford, and a JD from Harvard Law School.","Wilson's departure is not the result of any disagreement with Nektar on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132167,"accession_number":"0001213900-25-107821","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar reports REZOLVE-AD Phase 2b data showing asthma improvements with rezpegaldesleukin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Respegaldesleukin achieved statistically significant ACQ-5 reductions vs placebo in patients with AD and asthma (p<0.05).","In uncontrolled asthma subset (ACQ-5≥1.5, n=25), all doses showed significant ACQ-5 improvement; placebo-adjusted reductions 1.0–1.4.","Placebo crossover (n=42) at week 24: EASI-75 60%, vIGA-AD 0/1 33%, EASI-90 37%, Itch NRS response 50%.","Data support 24 μg/kg q2w dose with 24-week induction period for Phase 3 studies.","Top-line Phase 2b data in alopecia areata expected December 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132166,"accession_number":"0001213900-25-107180","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q3 net loss $35.5M ($1.87/sh), revenue $11.8M; cash $270.2M; rezpeg data at ACAAI","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.5M ($1.87/sh) vs $37.1M ($2.66/sh) in Q3 2024.","Revenue $11.8M, down from $24.1M YoY due to sale of Huntsville facility in Dec 2024.","Cash & marketable securities $270.2M as of Sep 30, 2025; includes $107.2M from July secondary offering.","R&D expense $27.3M vs $35.0M YoY; focus on rezpegaldesleukin, NKTR-0165, NKTR-422.","FDA granted Fast Track for rezpegaldesleukin in severe alopecia areata; topline data expected Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":33425000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148742,"accession_number":"0001213900-25-088792","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar Phase 2b rezpegaldesleukin meets primary endpoint; EASI-75 66% vs 34% placebo at week 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three rezpegaldesleukin dose arms met primary endpoint of mean % EASI improvement at week 16 (p<0.001 vs placebo).","High dose (24 µg/kg q2w) achieved statistical significance on EASI-75 (66% vs 34%), vIGA-AD 0/1 (19% vs 8%), and Itch NRS (42% vs 16%) at week 16.","Placebo crossover to high dose showed deepening response: EASI-75 62% and vIGA-AD 0/1 38% at week 24.","Safety consistent with prior data; most common AE mild injection site reactions; one death in escape arm assessed unrelated.","Next milestones: maintenance data Q1 2026; alopecia areata data Dec 2025; Phase 3 planning underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148741,"accession_number":"0001213900-25-073100","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q2 net loss $41.6M; rezpegaldesleukin Fast Track; cash runway into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.2M Q2 2025 vs $23.5M Q2 2024; decrease due to sale of Huntsville facility.","Net loss $41.6M ($2.95 per share) vs $52.4M loss ($3.76 per share) in Q2 2024.","Cash and investments $175.9M at June 30, 2025; excludes $107.5M net proceeds from July 2025 offering; runway into Q1 2027.","FDA Fast Track granted for rezpegaldesleukin in severe-to-very severe alopecia areata (July 2025).","REZOLVE-AD Phase 2b met primary and key secondary endpoints at week 16; 52-week data expected early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":21635000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148740,"accession_number":"0001193125-25-154062","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nektar Therapeutics prices $100M public offering at $23.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nektar prices 4,255,320 shares at $23.50/share for gross proceeds of $100M.","Net proceeds estimated at $93.7M ($107.8M if underwriters' option exercised in full).","Offering expected to close July 2, 2025; Jefferies and Piper Sandler are joint bookrunners.","Proceeds to fund R&D, clinical development, manufacturing, and other general corporate purposes.","Underwriters have a 30-day option to purchase up to an additional 638,298 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167620,"accession_number":"0001213900-25-059115","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nektar Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on April 3, 2025 for bid price below $1.00.","Regained compliance on June 23, 2025 after 10 consecutive trading days above $1.00.","Nasdaq confirmed compliance in a letter dated June 24, 2025.","Company continues to trade on The Nasdaq Capital Market under symbol NKTR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167619,"accession_number":"0001213900-25-056909","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar’s rezpegaldesleukin meets primary & key secondary endpoints in Phase 2b atopic dermatitis trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["REZOLVE-AD met primary endpoint: mean EASI improvement from baseline at week 16 for all three rezpegaldesleukin dose arms vs placebo (p<0.001).","EASI-75 achieved by 42-46% of rezpegaldesleukin patients vs 17% placebo; high dose also significant on EASI-90 (25% vs 9%).","Itch NRS (≥4-point reduction) 42% high dose, 35% middle dose vs 16% placebo; vIGA-AD 0/1 significant for q2w arms.","Safety profile consistent: injection site reactions (69.7%) mostly mild/moderate; no increased conjunctivitis, oral ulcers, or infections.","On-target Treg proliferation up to 6-fold; full 52-week data expected early 2026, alopecia areata top-line Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167618,"accession_number":"0001213900-25-052141","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nektar boosts authorized shares to 390M, completes 1-for-15 reverse split effective June 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 300M to 390M, effective June 6, 2025, stockholder-approved May 23, 2025.","Reverse stock split at 1-for-15 ratio effective 11:59 p.m. ET June 8; split-adjusted trading starts June 9 under NKTR.","Fractional shares rounded up at DTC for directly held shares; rounded down to nearest whole share for equity awards.","Total authorized shares remain at 390M after reverse split due to prior increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167617,"accession_number":"0001213900-25-051191","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nektar Therapeutics announces 1-for-15 reverse stock split effective June 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-15 reverse stock split effective June 8, 2025 at 11:59 p.m. ET.","Stockholders authorized reverse split ratio up to 1:40 at May 23 annual meeting; Board selected 1:15.","Split-adjusted trading begins June 9 under symbol NKTR with new CUSIP 640268306.","No fractional shares issued; rounding up for DTC participants, down for stock awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167616,"accession_number":"0001213900-25-047890","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nektar shareholders approve authorized share increase to 390M and reverse split authorization","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 5: authorized common shares increased from 300M to 390M (92.5M for, 55.5M against).","Proposal 6: Board authorized to effect reverse stock split at ratio 1:2 to 1:40 within one year (140M for).","Proposal 2: 2017 Performance Incentive Plan amended to add 6M shares (72.4M for, 28.8M against).","Directors Diana Brainard and R. Scott Greer elected; other directors continue.","Ernst & Young ratified as auditor; say-on-pay advisory resolution passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167615,"accession_number":"0001213900-25-041085","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q1 net loss $50.9M, cash $220.7M; Phase 2 data expected June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & marketable securities $220.7M, expected to fund operations into Q4 2026.","Revenue $10.5M, down from $21.6M YoY due to sale of Huntsville facility.","Net loss $50.9M ($0.24/share) vs $36.8M ($0.19) in Q1 2024; non-GAAP loss $46.4M.","Topline Phase 2 data for rezpegaldesleukin in atopic dermatitis expected June 2025.","FDA granted Fast Track designation for rezpegaldesleukin in atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":10460000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167614,"accession_number":"0001213900-25-029002","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nektar receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 3, 2025 for non-compliance with minimum bid price rule.","Must regain compliance by September 30, 2025; closing bid price must be at least $1.00 for 10 consecutive days.","If not compliant by deadline, Nasdaq may grant second 180-day grace period subject to conditions.","Company intends to monitor bid price and consider options to regain compliance; no guarantee of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184903,"accession_number":"0001013762-25-004236","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nektar enters ATM equity distribution agreement for up to $75M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM equity distribution agreement with Piper Sandler and BTIG allows sale of up to $75M of common stock.","Shares sold via at-the-market offerings on Nasdaq; agents receive 3.0% commission on gross proceeds.","Company has no obligation to sell any shares; either party may suspend or terminate the offering.","Registration statement on Form S-3 filed on March 28, 2025, for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184902,"accession_number":"0001213900-25-023220","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Therapeutics reports Q4 net income $7.3M; rezpegaldesleukin Phase 2b data expected in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $7.3M ($0.03 EPS) vs net loss $42.1M in Q4 2023; full year net loss $119M vs $276.1M.","Revenue Q4 $29.2M (+22% YoY); cash $269.1M, expected to fund operations into Q4 2026.","Rezpegaldesleukin Phase 2b topline data: atopic dermatitis in Q2 2025, alopecia areata in Q4 2025.","FDA granted Fast Track designation for rezpegaldesleukin in moderate-to-severe atopic dermatitis.","Sold PEGylation manufacturing business for $90M enterprise value ($70M cash + $20M equity)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184901,"accession_number":"0001213900-25-016278","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nektar partners with TrialNet for Phase 2 study of rezpegaldesleukin in type 1 diabetes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TrialNet will conduct a Phase 2 randomized, placebo-controlled trial in ~70 adults and children with new onset stage 3 T1D.","Nektar supplies rezpegaldesleukin, retains all program rights; TrialNet funds the study via NIH.","Study aims to preserve beta-cell function using MMTT-measured C-peptide over 12 months; initiation targeted for 2025.","Rezpegaldesleukin is also in Phase 2b trials for atopic dermatitis (REZOLVE-AD) and alopecia areata (REZOLVE-AA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184900,"accession_number":"0001213900-25-010085","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nektar CMO Mary Tagliaferri resigns; Brian Kotzin named interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Tagliaferri resigned as SVP and CMO effective Feb 4, 2025, for personal reasons; no disagreement with company.","Brian Kotzin, MD, appointed interim CMO; he previously served as strategic advisor for rezpegaldesleukin program since April 2023.","Kotzin has over 40 years immunology experience; was VP at Amgen and held academic positions; will assist search for permanent CMO.","Kotzin currently serves on boards of Argenx SE, Biora Therapeutics, and Genascence Corporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201496,"accession_number":"0001213900-24-104240","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Nektar completes sale of Huntsville manufacturing facility to Ampersand affiliate","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Closed disposition of Huntsville, AL manufacturing facility and related assets to an affiliate of Ampersand Capital Partners.","Transaction completed on December 2, 2024, as previously announced on November 4, 2024.","Purchaser assumed certain related liabilities; no financial terms disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201495,"accession_number":"0001213900-24-095423","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q3 net loss narrows to $37.1M; sells Huntsville business for $90M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $37.1M ($0.18/sh) vs $45.8M ($0.24) in Q3 2023; revenue flat at $24.1M.","Cash & investments $249M as of Sep 30; expected to fund operations into Q4 2026.","Definitive agreement to sell Huntsville PEGylation business to Ampersand for $90M ($70M cash + $20M equity).","R&D expense rose to $35.0M from $24.1M, driven by rezpegaldesleukin and NKTR-0165 development.","Topline data for rezpegaldesleukin Phase 2b in atopic dermatitis expected H1 2025; alopecia areata H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201494,"accession_number":"0001213900-24-093768","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Nektar to sell Huntsville PEGylation plant to Ampersand for $90M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total consideration $90M ($70M cash, $20M equity in new Ampersand portfolio co.).","Expected close by Dec 2, 2024; all Huntsville employees offered jobs at new co.","Nektar retains existing royalty/milestone rights; enters supply agreements for PEG reagents.","Sale not subject to financing; extends Nektar cash runway into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217495,"accession_number":"0001213900-24-066630","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q2 net loss $52.4M, cash $290.6M, rezpegaldesleukin Phase 2b on track for H1 2025 topline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2024 $52.4M ($0.25/share) vs $51.1M ($0.27) Q2 2023; non-GAAP net loss $39.1M ($0.19).","Cash and investments $290.6M at June 30, 2024, down from $329.4M at Dec 31, 2023; runway into Q3 2026.","Revenue Q2 2024 $23.5M vs $20.5M Q2 2023; R&D expense flat at $29.7M; non-cash restructuring/impairment $13.3M.","Rezpegaldesleukin Phase 2b enrollment on track; topline data expected H1 2025 (atopic dermatitis) and mid-2025 (alopecia areata)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":45128000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237375,"accession_number":"0001213900-24-050365","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nektar shareholders elect three directors, approve 8M share increase, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Jeff Ajer, Robert B. Chess, Roy A. Whitfield with broker non-votes of 46.7M each.","Approved amendment to 2017 Performance Incentive Plan adding 8M shares; 86.5M for, 7.5M against.","Ratified Ernst & Young as independent auditor for FY2024: 139M for, 1.6M against, 6M abstain.","Non-binding say-on-pay approved: 87M for, 6.7M against, 6.2M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237374,"accession_number":"0001213900-24-041325","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q1 net loss narrows to $36.8M; REZPEG Phase 2b on track for H1 2025 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue flat at $21.6M; net loss of $36.8M ($0.19/share) vs $137M loss YoY, improved on lower costs.","Cash and securities $326M; expects to fund operations into Q3 2026.","R&D expense $27.4M, down from $30.5M YoY; G&A $20.1M vs $21.1M.","Phase 2b REZPEG studies in atopic dermatitis and alopecia areata enrolling; topline data H1 2025.","Raised $30M gross via private placement in March 2024 with TCG Crossover Fund."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":21639000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237373,"accession_number":"0001213900-24-033856","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nektar Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on April 17, 2024, confirming compliance regained as of April 16, 2024.","Common stock closing bid price met $1.00 minimum for 10 consecutive business days.","Stock had been non-compliant since May 2023 and transferred to Nasdaq Capital Market in November 2023.","Additional 180-day extension had been granted until May 20, 2024.","Continued listing on Nasdaq Capital Market is now secure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254911,"accession_number":"0001213900-24-019557","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Nektar Q4 net loss $42.1M; cash $329.4M; $15M royalty amendment & $30M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $23.9M (up from $22.0M); Q4 net loss $42.1M ($0.22/sh) vs $59.7M ($0.32).","Cash and investments $329.4M at Dec 31, 2023, down from $505.0M; runway into Q3 2026.","Received $15M from Healthcare Royalty to cancel reversionary interest in royalties.","Completed $30M private placement with TCG Crossover Fund in March 2024.","Phase 2b study of rezpegaldesleukin for atopic dermatitis initiated; data expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254910,"accession_number":"0001193125-24-056966","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nektar Therapeutics raises $30M via pre-funded warrant to TCG Crossover Fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued pre-funded warrant to purchase 25M shares of common stock at $1.20 per share, total $30M.","Exercise price of warrant is $0.0001 per share; purchaser cannot exceed 9.99% beneficial ownership without notice.","Closing expected on or before March 6, 2024; exempt from registration under Section 4(a)(2) and Rule 506(b).","Company to file resale registration statement for warrant shares within 90 days after closing.","Use of proceeds not specified; proceeds before expenses are $30M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254909,"accession_number":"0001213900-24-014968","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.02","1.01","8.01"],"status":"ready","headline":"Nektar repurchases 8.28M shares from BMS for $3M; reduces outstanding shares by 4.34%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased 8,284,600 BMS-held restricted shares for $3,000,000 aggregate.","Stock repurchase reduces outstanding shares by ~4.34% based on Nov 2023 10-Q count.","2018 Share Purchase Agreement and Investor Agreement with BMS terminated.","Reduction reflected in weighted-average shares for quarter ending June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254908,"accession_number":"0001213900-24-002718","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Nektar reports $329M cash; runway into mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and cash equivalents of $329 million as of December 31, 2023.","Cash runway expected to fund operations into at least mid-2026.","Management announced at J.P. Morgan Healthcare Conference on January 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272394,"accession_number":"0001213900-23-090252","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nektar gets Nasdaq bid-price extension to May 2024; stock moves to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted additional 180-day period until May 20, 2024 to regain $1.00 minimum bid price.","Common stock will transfer from Nasdaq Global Select to Nasdaq Capital Market on Nov 28, 2023.","Company intends to cure deficiency via reverse stock split if needed before May 20, 2024.","If compliance not regained, Nasdaq may delist NKTR; company can appeal to a Listing Qualifications panel.","Stock continues to trade under symbol NKTR on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272393,"accession_number":"0001213900-23-084317","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar reports Q3 net loss $45.8M, cash $372.7M; Phase 2b atopic derm study initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $45.8M ($0.24/shr) vs $59.0M y/y; non-GAAP loss $35.7M ($0.19/shr).","Revenue $24.1M, slightly up from $23.6M y/y; cash $372.7M, down from $505.0M at year-end.","Initiated Phase 2b study of rezpegaldesleukin in atopic dermatitis (Oct 2023); Phase 2b alopecia areata to start early 2024.","Clinical collaboration with CBMG to evaluate NKTR-255 in combination with TIL therapy in NSCLC.","R&D expense reduced to $24.1M (Q3) due to wind-down of bempegaldesleukin program."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":66237000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289216,"accession_number":"0001213900-23-075473","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Nektar terminates collaboration agreement with Bristol-Myers Squibb for bempegaldesleukin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Parties entered letter agreement on Sept 6, 2023 to terminate the 2018 Strategic Collaboration Agreement.","Collaboration covered development of bempegaldesleukin in combination with BMS's Opdivo (nivolumab).","Global clinical development program for the combination was already ended in April 2022.","Termination effective immediately per the letter agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289215,"accession_number":"0001213900-23-064560","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Therapeutics Q2 net loss narrows to $51.1M; cash $409.4M, runway into mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.1M ($0.27/shr) vs $159.1M loss in Q2 2022; revenue $20.5M vs $21.6M.","Cash and marketable securities $409.4M, down from $505.0M at Dec 31, 2022; expects to fund ops into mid-2026.","R&D expense $29.7M (down 30% YoY) due to bempegaldesleukin wind-down; restructuring charges $16.6M.","Plans Phase 2b study of rezpegaldesleukin in atopic dermatitis; initial data in H1 2025; IND submission in 2024.","Corrected rezpegaldesleukin efficacy data previously miscalculated by Eli Lilly; evaluating NKTR-255 partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":42093000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289214,"accession_number":"0001213900-23-063806","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar corrects REZPEG Phase 1b data; atopic dermatitis EASI-75 rate now 41% vs 29% reported by Lilly","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Highest REZPEG dose (24 µg/kg) in atopic dermatitis achieved 83% mean EASI improvement (p=0.002 vs placebo).","EASI-75 response rate corrected from previously reported 29% to 41% (NRI) and 58% as observed.","Psoriasis data also corrected: PASI-50 rate rose to 32% (NRI) and PASI-75 to 21% (NRI); p-values remained non-significant.","Errors discovered after Lilly returned rights; independent statistical firm reanalyzed raw data.","Nektar plans to start Phase 2b study in moderate-to-severe atopic dermatitis in October 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310000,"accession_number":"0001213900-23-051097","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nektar Therapeutics CFO separation agreement provides $880K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jillian Thomsen's employment terminated June 16, 2023; transition period from April 17.","Company to pay $880,000 lump sum severance, plus COBRA through June 30, 2024.","Career transition services and IT equipment benefits included in agreement.","Agreement contains standard release of claims and negative PTO balance waiver."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309999,"accession_number":"0001213900-23-047824","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nektar Therapeutics stockholders approve all proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Myriam J. Curet and Howard W. Robin to Board with 86.0M and 131.4M votes for, respectively.","Approved amendment to 2017 Plan to increase authorized shares by 12,000,000 (128.2M for).","Ratified Ernst & Young as fiscal 2023 auditor (152.2M for).","Advisory say-on-pay approved (114.5M for); frequency set at 1 year (131.8M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309998,"accession_number":"0001213900-23-045748","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nektar receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice dated May 26, 2023; stock closed below $1.00 for 30 consecutive business days.","Company has until November 22, 2023 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, may qualify for second 180-day period by transferring to Nasdaq Capital Market.","Company intends to monitor bid price and evaluate options including possible reverse stock split.","No immediate impact on listing; delisting possible if compliance not achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309997,"accession_number":"0001213900-23-037687","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q1 2023 net loss $137M; regains rezpegaldesleukin rights from Lilly","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $137.0M ($0.73/share) vs. $90.4M ($0.49) in Q1 2022.","Non-GAAP net loss of $47.3M ($0.25/share) excluding $89.7M in impairment charges.","Revenue $21.6M, down from $24.8M; R&D expense fell to $30.5M from $107.3M.","Cash and investments $456.8M; expected to fund operations into mid-2026.","Regained full rights to rezpegaldesleukin from Eli Lilly; plans Phase 2b atopic dermatitis study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":21594000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309996,"accession_number":"0001213900-23-033020","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Nektar regains full rights to REZPEG from Lilly; plans Phase 2b in atopic dermatitis in 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lilly terminated license agreement at will; termination effective July 22, 2023; Nektar gets all rights back.","Nektar plans to initiate a Phase 2b study in moderate-to-severe atopic dermatitis in 2023 and explore other auto-immune indications.","Phase 1b data showed dose-dependent improvement over placebo in EASI, EASI-75, vIGA-AD, and Itch NRS with durable response.","Termination does not impact Nektar's cash guidance as milestone payments were not included in forecasts.","CEO Howard Robin expresses confidence in REZPEG's potential as a remittive therapy for atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-27T23:59:59+00:00|309996"}